BAL30072

Class: Beta-lactam (siderophore-sulfactam)

Spectrum of activity:	Gram-negative
Details of activity:	MDR gram-negative infections
Propensity to select resistant mutants:	No (demonstrated high resistance)
Institute where first reported:	Basilea Pharmaceutica, Switzerland
Year first mentioned:	2008
Highest developmental phase:	Phase 1
Development status:	Discontinued
Reason Dropped:	Liver injury detected 3-days post treatment (iv formulation); preclinical studies of inhalation also terminated due to 'lack of confidence in candidate's success'

Chemical structure(s):
Canonical SMILES:	CC1(C)[C@@H](C(=O)N1OS(=O)(=O)O)NC(=O)/C(=N\OCC2=CC(=O)C(=CN2O)O)/C3=CSC(=N3)N
Isomeric SMILES:	CC1([C@@H](C(=O)N1OS(=O)(=O)O)NC(=O)/C(=N\OCC2=CC(=O)C(=CN2O)O)/C3=CSC(=N3)N)C
InChI:	InChI=1S/C16H18N6O10S2/c1-16(2)12(14(26)22(16)32-34(28,29)30)19-13(25)11(8-6-33-15(17)18-8)20-31-5-7-3-9(23)10(24)4-21(7)27/h3-4,6,12,24,27H,5H2,1-2H3,(H2,17,18)(H,19,25)(H,28,29,30)/b20-11-/t12-/m1/s1
InChI Key:	KLFSEZJCLYBFKQ-WXYNYTDUSA-N
Structure link:	https://pubchem.ncbi.nlm.nih.gov/compound/52942440

External links:
Guide to Pharmacology:	BAL30072
Main Source:	https://www.basilea.com/fileadmin/user_upload/pressreleases/766305-en-708837.pdf?v=1546612716
Citations:	http://aac.asm.org/content/57/5/2095.full https://www.escmid.org/escmid_publications/escmid_elibrary/?q=bal30072&id=2173&L=0&x=0&y=0 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3058568/